Dongwen Lv (Lyu)
University of Florida
H-index: 30
North America-United States
Top articles of Dongwen Lv (Lyu)
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
NSD2 overexpression drives multiple myeloma dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome | Cancer Research | Amin Sobh Elena Encinas Alisha Patel Greeshma Surapaneni Charlotte Kaestner | 2024/3/22 |
Abstract 1209 Structural And Biochemical Studies Of Proteolysis-Targeting Chimera (PROTAC) Against Oncogenic Anti-Apoptotic Proteins, BCL-xl And Bcl-2 | Journal of Biological Chemistry | Digant Nayak Dongwen Lyu Wanyi Hu Guangrong Zheng Daohong Zhao | 2024/3/1 |
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy | Journal of Experimental Medicine | Lei Wang Yufeng Xiao Yuewan Luo Rohan P Master Jiao Mo | 2024/2/9 |
Bifunctional Peptide Nanofibrils for Targeted Protein Degradation | Zongtao Lin Benjamin A Garcia Dongwen Lv | 2024/1/15 | |
NSD2 drives t (4; 14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome | Blood Journal | Amin Sobh Elena Encinas Alisha M Patel Greeshma Surapaneni Emilie Bonilla | 2024/4/10 |
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL | Nature communications | Digant Nayak Dongwen Lv Yaxia Yuan Peiyi Zhang Wanyi Hu | 2024/3/29 |
Therapeutic agents and methods of treatment | 2023/10/26 | ||
HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation | Cell chemical biology | Yufeng Xiao Seth Hale Nikee Awasthee Chengcheng Meng Xuan Zhang | 2023/11/16 |
Selective targeting deacetylase 3 (HDAC3) and HDAC8 by PROTACs | Cancer Research | Yufeng Xiao Seth Hale Nikee Awasthee Xuan Zhang Yi Liu | 2023/4/4 |
Characterizing cellular senescence response to senolytic compounds using cell culture media analysis | Cancer Research | Evelyn Wang Stephen Kurzyniec Ethan Hain Yoshiyuki Okamura Yang Yang | 2023/4/4 |
Automation to Enable High-Throughput Chemical Proteomics | Zongtao Lin Joanna Gongora Xingyu Liu Yixuan Xie Chenfeng Zhao | 2023/11/2 | |
Identification of Piperlongumine (PL) as a new E3 ligase ligand to induce targeted protein degradation | Cell Chemical Biology | Jing Pei Yufeng Xiao Xingui Liu Wanyi Hu Amin Sobh | 2022/1/23 |
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity | Nature communications | Dongwen Lv Pratik Pal Xingui Liu Yannan Jia Dinesh Thummuri | 2021/11/25 |
Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition | Journal of medicinal chemistry | Pratik Pal Dinesh Thummuri Dongwen Lv Xingui Liu Peiyi Zhang | 2021/9/17 |
Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity | Aging cell | Yonghan He Wen Li Dongwen Lv Xin Zhang Xuan Zhang | 2020/3 |
Protein inhibitor of activated STAT1 (PIAS1) inhibits IRF8 activation of Epstein-Barr virus lytic gene expression | Virology | Kun Zhang Dong-Wen Lv Renfeng Li | 2020/1/15 |
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies | Yonghan He Sajid Khan Zhiguang Huo Dongwen Lv Xuan Zhang | 2020/12 | |
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas | Journal of hematology & oncology | Yonghan He Raphael Koch Vivekananda Budamagunta Peiyi Zhang Xuan Zhang | 2020/12 |
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity | Nature communications | Yonghan He Xuan Zhang Jianhui Chang Ha-Neui Kim Peiyi Zhang | 2020/4/24 |
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines | European journal of medicinal chemistry | Xuan Zhang Yonghan He Peiyi Zhang Vivekananda Budamagunta Dongwen Lv | 2020/8/1 |
Co-Authors
